Panobinostat’s Questionable Magnitude Of Benefit Can’t Outweigh Toxicities, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis shouldn’t give up on drug for relapsed multiple myeloma, FDA’s Oncologic Drugs Advisory Committee says, even as panel votes against approval based on progression-free survival data.